ABSTRACT
Laminaria tents are used in obstetrics and gynecology for dilatation and/or ripening of the cervix. They are effective in labor induction, abortion, endometrial biopsy, treatment of cervical stenosis, difficulty in inserting and removing intrauterine pessaries.
Subject(s)
Abortion, Induced/instrumentation , Gynecologic Surgical Procedures/instrumentation , Labor, Induced/instrumentation , Female , Humans , Pregnancy , Uterus/surgeryABSTRACT
AIM: Our aim was to summarize our and foreign experience in the field of diagnosis, progression and modern treatment of precancer of the endometrium-the atypical glandular hyperplasia. MATERIAL AND METHODS: We researched 750 cases with glandular and atypical glandular hyperplasia for 10 years period (2000-2010). The hyperplasia were followed up for progression from glandular hyperplasia into atypical glandular hyperplasia and early endometrial cancer. The hyperplasias were evaluated with or without progestagen hormonal therapy. All patients were treated by D&C before and after the hormonal treatment. RESULTS: The main symptom in all patients was the postmenopausal bleeding (72% from the cases). In 90% of the patients (675) there was obesity. Exogenous use of estrogens was found in 30% (225) of the patients. The cases with complex hyperplasia in 12% (65/525) progressed into atypical glandular hyperplasia and in 4% (21/525) progressed into endometrial cancer. The patients with atypical glandular hyperplasia in 60% (90/150) progressed into endometrial cancer. Remission was observed in 70% of the patients (194/278) with glandular hyperplasia and progestagen treatment. The remission was detected by the golden standart (D&C). The patients without hormonal treatment and with complex glandular hyperplasia have in 15% (37/247) remission. Except with progestagen therapy, we have also 15 patients treated with GnRh-analogs (Zoladex a 3.6 mg) for 3-6 months. For them we have 80% (12/15) remission. CONCLUSIONS: The glandular hyperplasia without atypical cells can be influenced by the hormonal treatment with progestagens and GnRh-analogs. Nevertheless this hormonal treatment--before and after we have to perform D&C and to follow up patients by ultrasound measuring the endometrial thickness. If the fertility plans of the patients are over and if they are in postmenopause with histological result from D&C-atypical glandular hyperplasia--we have to treat them more radically with simple total hysterectomy.
Subject(s)
Antineoplastic Agents, Hormonal/therapeutic use , Endometrial Hyperplasia/drug therapy , Endometrial Neoplasms/drug therapy , Goserelin/therapeutic use , Progestins/therapeutic use , Disease Progression , Endometrial Hyperplasia/diagnosis , Endometrial Hyperplasia/pathology , Endometrial Neoplasms/diagnosis , Endometrial Neoplasms/pathology , Female , Follow-Up Studies , Gonadotropin-Releasing Hormone/analogs & derivatives , HumansABSTRACT
A new Soviet antioxidant drug, ubinon, has been used in 75 patients with coronary heart disease (CHD) of functional classes I-III, including 12 patients with ventricular extrasystoles. Treatment with placebo in 10 patients produced no improvement and had no effect on their stress tolerance. Ubinon, taken as 90 and 135 mg/day doses, was shown to produce clinical improvement and raise stress tolerance, mostly in first- and second-class cases. In coronary patients with ventricular extrasystoles, ubinon enhanced antiarrhythmic effect of mexitil. The use of ubinon was accompanied by a drop in blood oxidant activity and a rise in antioxidant activity, an increase in blood 6-keto-PGF1 alpha, a fall in TxB2 and a suppression of platelet activity. In addition, coronary patients with ventricular extrasystoles showed reduced cAMP and cGMP content and elevated cAMP/cGMP ratio.
Subject(s)
Antioxidants/administration & dosage , Coronary Disease/drug therapy , Lipid Peroxidation/drug effects , Adult , Aged , Clinical Trials as Topic , Coronary Disease/etiology , Coronary Disease/metabolism , Drug Therapy, Combination , Humans , Male , Middle Aged , Nitroglycerin/administration & dosage , PlacebosABSTRACT
Platelet function, lipid peroxidation, and levels of cholesterol, triglycerides, high density lipoprotein (HDLP) cholesterol and PGE1 and PGF2 alpha were assessed before and after 28-day administration of polyunsaturated fatty acids (PUFA), contained in olive, corn and cod oil, in 80 coronary patients. The use of PUFA is shown to have a favorable effect on platelet function, decreasing aggregation and increasing disaggregation of platelets. This effect may be due to increased PGE1, producing an antiaggregation effect, while cod oil may also increase HDLP. Additional administration of vitamin E and HDLP prevents unfavorable effects of increased lipid peroxidation.
Subject(s)
Blood Platelets/drug effects , Coronary Disease/drug therapy , Fatty Acids, Unsaturated/therapeutic use , Lipid Peroxides/blood , Adenosine Diphosphate/pharmacology , Adult , Aged , Angina Pectoris/blood , Angina Pectoris/drug therapy , Blood Platelets/physiology , Chronic Disease , Coronary Disease/blood , Drug Evaluation , Drug Therapy, Combination , Humans , Male , Middle Aged , Myocardial Infarction/blood , Myocardial Infarction/drug therapy , Oxidation-Reduction/drug effects , Physical Exertion , Platelet Aggregation/drug effects , Time Factors , Vitamin E/therapeutic useABSTRACT
A soy flour and oatmeal formula added with vitamins and minerals is presented. Nitrogen balance is carried out in 6 malnourished infants undergoing recovery as compared with a commercial milk formula, finding no significant statistical differences between the two formulas.
